Oncology at an Inflection Point: How Clinical Innovation is Fueling a New Wave of M&A

While consolidation of physician practices continues across a variety of specialties, therapeutic innovation is driving greater interest in oncology practices from both private equity and hospital systems. Rapid innovation, increasing complexity, and the capital-intensive nature of developing and commercializing new cancer therapies make the specialty particularly compelling.

The following factors help explain this dynamic:

Innovation and Complexity

• • • Innovation and novel therapies are driving an accelerated growth in oncology-related infusion, with the global market expected to grow over 7% per year into 2033.
    • Payers aggressively support the move of infusion services from high-cost hospital settings to the lower cost environments at physician offices, ambulatory surgery centers and dedicated infusion centers. The result, forecasted growth of 11% in oncology-related outpatient infusion services.
    • Advances in precision medicine, immunotherapy, bi-specific antibodies, synthetic lethality, and cell and gene therapies require specialized expertise, and infrastructure is, according to a TFS HealthScience, encouraging smaller players to partner with or be acquired by larger organizations capable of supporting complex clinical trials and commercialization. CAR-T cell infusion, as an example, is expected to reach $7.6 billion by 2026, a 39.1% CAGR (Compound Annual Growth Rate) since 2021.
    • Clinical development is accelerating and moving towards more patient-centric, inclusive, and biomarker-driven trials that need a broad resource base and sophisticated trial execution 2024 clinical trials were up 12% versus 2019.

Market and Reimbursement Dynamics

A Labiotech article states that the emergence of high value combination therapies and precision oncology treatments increases the financial stakes and reimbursement complexity, motivating providers and drug developers to consolidate to negotiate better payer arrangements and develop integrated care models.

The significant costs, working capital requirements and margin for new therapies are creating a new economic engine entities are trying to capture. Oncology practices rely heavily on the buy-and-bill model for infused therapies, which creates significant working capital requirements and financial risk, integrate drug development, testing, and delivery capabilities, creating dynamics that enhance clinical and commercial success in an increasingly competitive market, according to Blue Matter Consulting.

Oncology requires specialized infusion suites, nursing staff, and safety protocols for chemotherapy, immunotherapy, and biologics. Emerging therapies (CAR-T, bispecific antibodies) demand advanced monitoring and equipment. These capital-intensive requirements make scale advantageous, unlike primary care where infrastructure needs are minimal.

Investor Interest and Market Drivers

Investment activity in oncology remains strong, underpinned by a substantial pipeline of innovative therapies, rising demand for personalized treatment options, and the growing incidence of cancer diagnoses. The sector’s attractiveness to investors is further amplified by the breadth of ancillary services, compelling profit opportunities, and a highly fragmented market structure—factors that continue to draw interest from hospitals, corporate entities, and private equity investors.

The U.S. oncology market demonstrates robust growth potential, with projections indicating a compound annual growth rate depending on source from 9% to 12% between 2024 and 2034. Market size is expected to reach $170–$220 billion by 2034, reflecting sustained momentum across therapeutic and service segments. Investors are particularly focused on platforms that enable scalable, quality-driven care delivery models and incorporate ancillary services such as pharmacy and diagnostics, which enhance both operational efficiency and patient outcomes.

Select Relevant Transactions in Oncology

As a result of developing dynamics, a broader range of organizations have entered the fray of consolidation. In addition to private equity groups and health systems, large drug distributors (e.g., Cardinal Health, McKesson) and insurers (e.g., UnitedHealth/Optum) have also been increasingly active in acquiring or partnering with oncology and infusion platforms, further accelerating integration across the continuum of cancer care.

Below are recent notable transactions underscoring investor enthusiasm for clinically advanced oncology and infusion platforms.

Outlook

Looking ahead, oncology will remain one of the most compelling areas for healthcare investment. The convergence of breakthrough science, expanding infusion volumes, and increasingly capital-intensive care models will continue to favor scaled platforms with diversified services and robust clinical infrastructure. As payers push care into lower-cost settings and new therapies reshape the economics of cancer treatment, the competitive advantage will shift toward groups that can integrate pharmacy, diagnostics, and research into a cohesive operating model. The market is poised for another decade of strong growth, and strategic consolidation will remain a central path to capturing emerging value.

Summary Table: Recent Oncology Transactions